Effect of β-alanine Supplementation on Muscle Carnosine

Healthy Clinical Trial

— LitmusMagnet  

Official title:

Effect of Two 8-week β-alanine Supplementation Protocols on Muscle Carnosine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00813553
• Other study ID #: 08.13.PER
• Status: Completed
• Phase: N/A
• First received: December 22, 2008
• Last updated: April 24, 2012
• Start date: December 2008
• Est. completion date: October 2009

Study information

• Verified date: April 2012
• Source: Nestlé
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

Carnosine is a natural acid buffering substance of muscle. The primary objective of this study is to test whether a nutritional supplement of beta-alanine enhances carnosine content in muscle.

Description:

Volunteers will be randomized to receiving 3 nutritional supplements. Two supplements contain beta-alanine at different doses, the third supplement is a placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 2009
• Est. primary completion date: October 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Stable health as evaluated by medical evaluation

• Body mass index higher than 18 kg/m2

• Body mass index lower than 25 kg/m2, unless body fat is less than 20%

Exclusion Criteria:

• intolerance to ß-alanine,

• allergy to soy, fish and crustacean

• participation in another intervention study

• consumer of dietary supplement susceptible to contain beta-alanine

• determined to have very high baseline muscle carnosine concentration

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• placebo
daily
• beta-alanine
daily
• beta-alanine
daily

Locations

Country	Name	City	State
Switzerland	University and Inselspital	Bern

Sponsors (3)

Lead Sponsor	Collaborator
Nestlé	University Hospital Inselspital, Berne, University of Bern

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	muscle carnosine concentration		0 to 8 weeks	No